A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524640-35-00

Enrollment

102

Registered

2026-06-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis (Inflammatory Bowel Disease)

Brief summary

Incidence of TEAEs (treatment-emergent adverse event)

Detailed description

Endoscopic improvement at Week 48

Interventions

DRUGSPYPBO-101

DRUGSPY001-001

DRUGSPY003

DRUGSPY002

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of TEAEs (treatment-emergent adverse event)	—

Secondary

Measure	Time frame
Endoscopic improvement at Week 48	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 18, 2026